| Title | Update on fibromyalgia therapy. | | Author(s) | Abeles M, Solitar BM, Pillinger MH, Abeles AM | | Institution | Division of Rheumatology, Department of Medicine, The University of Connecticut School of Medicine, Farmington, USA. aabeles@uchc.edu | | Source | Am J Med 2008 Jul; 121(7):555-61. | | MeSH | Amines
Anti-Inflammatory Agents, Non-Steroidal
Anticonvulsants
Antidepressive Agents
Complementary Therapies
Cyclohexanecarboxylic Acids
Evidence-Based Medicine
Exercise Therapy
Fibromyalgia
Humans
gamma-Aminobutyric Acid
| | Abstract | Primary fibromyalgia, a poorly-understood chronic pain syndrome, is characterized by widespread musculoskeletal pain, nonrestorative sleep, fatigue, psychological distress, and specific regions of localized tenderness, all in the absence of otherwise apparent organic disease. While the etiology of fibromyalgia is unclear, accumulating data suggest that disordered central pain processing likely plays a role in the pathogenesis of symptoms. Although various pharmacological treatments have been studied and espoused for treating fibromyalgia, no single drug or group of drugs has proved to be particularly useful in treating fibromyalgia patients as a whole, and only one drug to date has earned U.S. Food and Drug Administration approval for treating the syndrome in the United States. This review critically and systematically evaluates clinical investigations of medicinal and nonmedicinal treatments for fibromyalgia dating from 1970 to 2007. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 18589048 |
|
